Post-earnings recap
Reported
Mon, Nov 10, 2025
EPS actual
$-1.01
EPS est.
$-0.88
EPS surprise
-14.51%
1-day move
-1.00%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 1.0% decline in stock price following the earnings announcement. The lack of revenue figures and guidance may leave investors uncertain about the company's short-term outlook. Management's defensive tone suggests they are aware of the challenges ahead and are focused on improving operations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.01 | N/A | -14.51% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concerns about the current market conditions. They highlighted their commitment to improving performance despite the setbacks.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to enhance operational efficiency.